Convulsions after ropivacaine 300 mg for brachial plexus block.

A healthy 18-yr-old male (weight 60 kg, height 167 cm), with a history of febrile convulsions in childhood, developed a grand mal convulsion 10 min after the second of two injections of ropivacaine 150 mg, both given incrementally 15 min apart (total 300 mg), for combined axillary/interscalene brachial plexus block. Treatment was with oxygen, lung ventilation, and i.v. midazolam, and the patient made a complete recovery. Arterial plasma ropivacaine concentration 2 min after the onset of convulsions was only 2.13 mg litre(-1), suggesting that this patient was particularly susceptible to local anaesthetic toxicity. Whether sub-clinical EEG changes identified after operation were related to this sensitivity cannot be determined, but review illustrates wide variation in both the dose and the plasma concentration of local anaesthetics associated with systemic toxicity. The UK recommended dose of ropivacaine for brachial plexus block is 225-300 mg according to stature.

[1]  Y. Kimura,et al.  Ropivacaine-induced toxicity with overdose suspected after axillary brachial plexus block , 2007, Journal of Anesthesia.

[2]  S. Stehr,et al.  Successful resuscitation of a patient with ropivacaine‐induced asystole after axillary plexus block using lipid infusion * , 2006, Anaesthesia.

[3]  R. Post,et al.  The effect of amygdala kindling on spontaneous and cocaine-induced motor activity and lidocaine seizures , 2004, Psychopharmacology.

[4]  R. Litz,et al.  Grand mal convulsion and plasma concentrations after intravascular injection of ropivacaine for axillary brachial plexus blockade. , 2001, British journal of anaesthesia.

[5]  M. Crosse,et al.  Blind nasal intubation and a telephone directory. , 2000, Anaesthesia and intensive care.

[6]  L. Dumont,et al.  Convulsions after the administration of high dose ropivacaine following an interscalenic block , 2000, Canadian journal of anaesthesia = Journal canadien d'anesthesie.

[7]  J. Eledjam,et al.  Ropivacaine overdose and systemic toxicity. , 2000, Anaesthesia and intensive care.

[8]  P. Mowinckel,et al.  Axillary brachial plexus block with ropivacaine 7.5 mg/ml , 1999, Acta anaesthesiologica Scandinavica.

[9]  Tanaka In vivo age‐related changes in hepatic drug‐oxidizing capacity in humans , 1998, Journal of clinical pharmacy and therapeutics.

[10]  K.,et al.  Central nervous and cardiovascular effects of i.v. infusions of ropivacaine, bupivacaine and placebo in volunteers. , 1997, British journal of anaesthesia.

[11]  S. Imaoka,et al.  Metabolism of a New Local Anesthetic, Ropivacaine, by Human Hepatic Cytochrome P450 , 1995, Anesthesiology.

[12]  J. Graham-Pole,et al.  Phase II Trial , 1994, Annals of Internal Medicine.

[13]  J. Bevan Propofol-related convulsions , 1993, Canadian journal of anaesthesia = Journal canadien d'anesthesie.

[14]  C. Goodchild,et al.  Anticonvulsant properties of propofol and thiopentone: comparison using two tests in laboratory mice. , 1990, British journal of anaesthesia.

[15]  Alistair Lee,et al.  Acute Toxicity of Ropivacaine Compared with That of Bupivacaine , 1989, Anesthesia and analgesia.

[16]  Brown Tr Paraldehyde, chlormethiazole, and lidocaine for treatment of status epilepticus. , 1983 .